This publication highlights expert perspectives on the current therapeutic landscape in chronic lymphocytic leukemia with emphasis on factors affecting treatment selection including novel regimens, combination therapies, and ongoing clinical trials.
New Directions in CLL
Richard R. Furman, MD, discusses current treatment options in chronic lymphocytic leukemia.
Benjamin Heyman, MD, discusses the phase 3 ALPINE trial in chronic lymphocytic leukemia.
Shuo Ma, MD, PhD, discusses the utilization of zanubrutinib in chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5